Low-dose aspirin and survival from lung cancer: a population-based cohort study

BMC Cancer

Table 2 Association between low-dose aspirin usage after cancer diagnosis and cancer-specific and all-cause mortality in lung cancer patients

Medication usage after diagnosis	Cancer-specific deaths	All-cause mortality	All patients	Person years	Cancer-specific mortality						All-cause mortality
Medication usage after diagnosis	Cancer-specific deaths	All-cause mortality	All patients	Person years	Unadjusted		P	Adjusted^a		P	Unadjusted		P	Adjusted^a		P
					HR	95 % CI		HR	95 % CI		HR	95 % CI		HR	95 % CI
Number of patients					[n = 3,635]			[n = 2,791]			[n = 3,635]			[n = 2,791]
Aspirin non-user	1,609	1,855	2,474	4,481	1.00	Referent		1.00	Referent		1.00	Referent		1.00	Referent
Aspirin user^b	638	795	1,161	2,264	0.96	0.87, 1.05	0.36	0.96	0.85, 1.09	0.55	1.00	0.92, 1.09	0.92	0.94	0.84, 1.05	0.28
Aspirin non-user	1,609	1,855	2,474	4,481	1.00	Referent		1.00	Referent		1.00	Referent		1.00	Referent
Aspirin user 1 to 11 prescriptions^c	440	521	670	1,189	0.94	0.85, 1.04	0.25	0.95	0.83, 1.08	0.42	0.97	0.88, 1.07	0.60	0.93	0.83, 1.05	0.24
Aspirin user ≥ 12 prescriptions^c	198	274	491	1,075	1.00	0.86, 1.17	0.96	1.01	0.84, 1.23	0.89	1.07	0.94, 1.23	0.29	0.97	0.82, 1.14	0.69
Aspirin non-user	1,609	1,855	2,474	4,481	1.00	Referent		1.00	Referent		1.00	Referent		1.00	Referent
Aspirin user 1–365 tablets^c	353	422	541	926	0.91	0.81, 1.02	0.12	0.92	0.80, 1.06	0.27	0.96	0.86, 1.07	0.44	0.92	0.81, 1.05	0.21
Aspirin user ≥366 tablets^c	285	373	620	1,338	1.03	0.90, 1.17	0.69	1.04	0.88, 1.23	0.67	1.07	0.95, 1.20	0.28	0.97	0.84, 1.13	0.72

^aAdjusted for year of diagnosis, age at diagnosis, gender, radiotherapy within 6 months, chemotherapy within 6 months, surgery within 6 months, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (after diagnosis, as time varying covariates, specifically statins and beta-blockers) and deprivation (in fifths)
^bMedication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage and a user after this time, excludes deaths in the year after cancer diagnosis
^cMedication use modelled as a time varying covariate with an individual considered a non-user prior to 6 months after first medication usage, a user of 0 to 12 prescriptions from 6 months after first prescription to 6 months after 12^th prescription (or 365 tablets) and a greater user after this time, excludes deaths in the year after cancer diagnosis

ISSN: 1471-2407